| Schedule of Segment Reporting Information, by Segment |
The following table is a comparative summary of the Company’s net sales and segment profit for by reportable segment for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended |
| |
|
|
|
December 31,
2023 |
|
December 31,
2022 |
Segment Net Revenue: |
|
|
|
|
|
|
|
| Cannabinoid |
|
|
|
|
$ |
6,558
|
|
|
$ |
4,729 |
|
| Non-Cannabinoid |
|
|
|
|
10,859
|
|
|
11,681 |
|
| Total Net Revenue |
|
|
|
|
17,417
|
|
|
16,410 |
|
| |
|
|
|
|
|
|
|
Segment Profit (Loss):
|
|
|
|
|
|
|
|
| Cannabinoid |
|
|
|
|
(10,783) |
|
|
(17,354) |
|
| Non-Cannabinoid |
|
|
|
|
2,247
|
|
|
1,346 |
|
| Total Loss |
|
|
|
|
$ |
(8,536) |
|
|
$ |
(16,008) |
|
| |
|
|
|
|
|
|
|
Reconciliation:
|
|
|
|
|
|
|
|
| Total Segment Loss |
|
|
|
|
(8,536) |
|
|
(16,008) |
|
| Unallocated corporate expenses |
|
|
|
|
(7,221) |
|
|
(8,328) |
|
| Non-cash share based compensation |
|
|
|
|
(818) |
|
|
(2,343) |
|
| Depreciation and amortization |
|
|
|
|
981
|
|
|
(1,240) |
|
|
|
|
|
|
|
|
|
| Intangible Asset Impairment |
|
|
|
|
—
|
|
|
(19,000) |
|
| Loss from operations |
|
|
|
|
$ |
(15,594) |
|
|
$ |
(46,919) |
|
| |
|
|
|
|
|
|
|
| Loss on debt extinguishment, net |
|
|
|
|
—
|
|
|
2,263 |
|
| Gain on remeasurement of warrant liability |
|
|
|
|
(113) |
|
|
(2,092) |
|
| Loss (Gain) on investment |
|
|
|
|
3,738
|
|
|
(6,851) |
|
| Foreign exchange loss |
|
|
|
|
433
|
|
|
963 |
|
| Interest expense |
|
|
|
|
46
|
|
|
2,672 |
|
| Other expense (income), net |
|
|
|
|
31
|
|
|
220 |
|
|
|
|
|
|
|
|
|
| Loss from operations before income taxes and equity investment loss |
|
|
|
|
$ |
(19,729) |
|
|
$ |
(44,094) |
|
The following table disaggregates the Company’s long-lived assets, by segment for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
2023 |
|
December 31,
2022 |
Long-lived assets
|
|
|
|
| Cannabinoid |
$ |
13,756
|
|
|
$ |
15,308 |
|
Non-Cannabinoid |
65
|
|
|
155 |
|
| Total |
$ |
13,821
|
|
|
$ |
15,463 |
|
|
| Schedule of Revenue by Major Customers by Reporting Segments |
Customers with an accounts receivable balance of 10% or greater of total accounts receivable and customers with net revenue of 10% or greater of total revenues are presented below for the periods indicated:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of Revenues |
|
Percentage of Accounts Receivable |
|
December 31, |
|
December 31, |
|
2023 |
2022 |
|
2023 |
2022 |
Customer A (b)
|
12% |
13% |
|
16% |
18% |
Customer B (a)
|
12% |
* |
|
* |
* |
|
|
|
|
|
|
|
|
|
|
|
|
Customer E (a)
|
* |
* |
|
* |
10% |
Customer F (a)
|
* |
* |
|
20% |
13% |
Customer G (a)
|
* |
* |
|
13% |
* |
Customer H (a)
|
* |
* |
|
12% |
* |
|
|
|
|
|
|
* denotes less than 10%
(a) net sales attributed are reflected in the cannabinoid segments
(b) net sales attributed are reflected in the non-cannabinoid segments
|
| Schedule of Disaggregation of Revenue |
The following table disaggregates the Company’s revenues by channel for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended |
|
|
|
|
|
December 31,
2023 |
|
December 31,
2022 |
| Mass retail |
|
|
|
|
$ |
11,377
|
|
|
$ |
8,531 |
|
| Distributors |
|
|
|
|
4,838
|
|
|
6,796 |
|
| Specialty, health and other retail |
|
|
|
|
255
|
|
|
577 |
|
| E-commerce |
|
|
|
|
947
|
|
|
506 |
|
|
|
|
|
|
$ |
17,417
|
|
|
$ |
16,410 |
|
|
| Schedule of Revenue from External Customers by Geographic Areas |
The following table represents the Company's revenues attributed to countries based on location of customer:
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
2023 |
2022 |
| United States |
$ |
10,859
|
|
|
11,461 |
| Israel |
600
|
|
|
991 |
| Australia |
1,683
|
|
|
1,455 |
| Brazil |
3,099
|
|
|
1,431 |
| Germany |
235
|
|
|
839 |
| Other |
941
|
|
|
233 |
| Total |
$ |
17,417
|
|
|
$ |
16,410 |
|
(a) The Company has presented December 31, 2022 information to conform to the current period presentation.
|